Current United States Food & Drug Administration approved indications for immune checkpoint inhibitors
| Agent | Target | Indication | Treatment line | Year |
| Atezolizumab | PD-L1 | NSCLC, advanced | Second | 2016 |
| Urothelial carcinoma, advanced | Second | 2016 | ||
| Avelumab | PD-L1 | Merkel cell carcinoma | First/second | 2017 |
| Urothelial carcinoma, advanced | Second | 2017 | ||
| Durvalumab | PD-L1 | Urothelial carcinoma, advanced | Second | 2017 |
| Ipilimumab | CTLA4 | Melanoma, advanced | Second | 2011 |
| Melanoma, advanced | First (+ nivolumab) | 2015 | ||
| Melanoma, stage III | Adjuvant | 2015 | ||
| Nivolumab | PD-1 | Melanoma, advanced | Second | 2014 |
| Melanoma, advanced | First (+ ipilimumab) | 2015 | ||
| NSCLC, advanced | Second | 2015 | ||
| RCC, advanced | Second | 2015 | ||
| Classic Hodgkin's lymphoma | Fourth | 2016 | ||
| H&N SCC, recurrent or advanced | Second | 2016 | ||
| Urothelial carcinoma, advanced | Second | 2017 | ||
| Pembrolizumab | PD-1 | Melanoma, advanced | Second | 2014 |
| NSCLC | Second if PD-L1 overexpressed =1% | 2015 | ||
| Melanoma, advanced | First | 2015 | ||
| H&N SCC, advanced | Second | 2016 | ||
| NSCLC | First if PD-L1 overexpressed =50% | 2016 | ||
| Classic Hodgkin's lymphoma | Fourth | 2017 | ||
| Urothelial carcinoma, advanced | Second | 2017 | ||
| NSCLC, non-SCC | First (+ pemetrexed and carboplatin) | 2017 | ||
| MSI-high cancer | Second | 2017 |
CTLA4: cytotoxic T-lymphocyte associated protein 4. H&N: head and neck. MSI: microsatellite instable. NSCLC: non-small cell lung cancer. PD-1: programmed death-1 checkpoint inhibitor. PD-L1: programmed death ligand-1. SCC: squamous cell carcinoma.